Hani Friedman Bouganim, Executive Vice President of Manufacturing, Quality and Supply Chain (Industrial Operations) at Servier, shared on LinkedIn:
“Expertise is at the heart of Industry, and sharing it is how we prepare the next generation.
Over two days at Servier Gidy, we experienced two complementary dimensions of our Industry.
The first brought together the President of Servier, Olivier Laureau, members of the Executive Committee Claude Bertrand, Pascal Lemaire, and our Gidy teams.
It was a warm and valuable opportunity to spend time on the ground, listen to our colleagues, and exchange openly about safety, quality, digital and AI and the priorities shaping the campus.
The second gave us the privilege of hosting the regional opening of French Industry Week in the Centre-Val de Loire Region, in the presence of the Prefect, the President of the Region, and a representative of the DRAFPIC, alongside representatives from across the region’s economic, educational, and institutional ecosystem, as well as a class of secondary school students discovering the pharmaceutical industry first-hand.

These moments highlighted what makes our Industry strong:
- The expertise and commitment of our teams
- Close cooperation with our local ecosystem
- The opportunity to introduce young people to the diversity and purpose of our professions
Our industrial performance has a clear purpose: ensuring quality, safety, and reliable supply for patients.
A sincere thank you to the entire Gidy team for making these two days possible.
Proud of what we are building and transmitting together!”
About Servier
Servier is an independent pharmaceutical company based in Suresnes, France. Founded in 1954, it develops and produces medicines with the aim of improving treatment options and meeting patients’ needs.
The company operates in more than 130 countries and has over 20,000 employees worldwide. Its main areas of focus include oncology, cardiometabolism, venous diseases and neurology. In recent years, oncology has become a major part of its work, with a focus on developing new treatments for challenging and rare cancers.
Servier is owned by a non-profit foundation, which allows it to remain independent and focus on long-term research and development. The company also invests a significant share of its revenue in developing new medicines and advancing medical research.
You may also be interested in: